# Supplementary Materials for

## Whole-Exome Mutational Landscape of Neuroendocrine Carcinomas of

## the Gallbladder

Fatao Liu, Yongsheng Li, Dongjian Ying, Shimei Qiu, Yong He, Maolan Li, Yun Liu, Yijian Zhang, Qin zhu, Yunping Hu, Liguo Liu, Guoqiang Li, Weihua Pan, Wei Jin, Jiasheng Mu, Yang Cao, Yingbin Liu

Correspondence to: mujiasheng@xinhuamed.com.cn; 2316029@zju.edu.cn; laoniulyb@shsmu.edu.cn

#### This PDF file includes:

Supplementary Figures. S1 to S20

#### Other Supplementary Materials for this manuscript include the following:

Data S1 to S19 (separate file)

Supplementary Table S1 Clinical information on the 22 GBC patients.

**Supplementary Table S2** Detailed information on the mutations detected in 15 GB-NECs. **Supplementary Table S3** Detailed information on known hotspot mutations detected in GB-NEC and GBC samples.

Supplementary Table S4 SMG analysis results in GB-NECs.

Supplementary Table S5 List of SMGs in the four reported kinds of neuroendocrine cancers.

Supplementary Table S6 Detailed information on the mutations detected in 22 GBCs.

Supplementary Table S7 Pathway analysis results of genes mutated in GB-NECs but not GBCs.

Supplementary Table S8 Pathway analysis results of genes mutated in both GB-NECs and GBCs.

Supplementary Table S9 CNV events detected in GB-NEC samples.

Supplementary Table S10 CNV events detected in GBC samples.

**Supplementary Table S11** Pathway analysis results of genes with a copy number gain in GB-NECs. **Supplementary Table S12** Pathway analysis results of genes with a copy number gain in GBCs.

Supplementary Table S13 Pathway analysis results of genes with a copy number loss in GB-NECs.

Supplementary Table S14 Pathway analysis results of genes with a copy number loss in GBCs.

**Supplementary Table S15** Detailed information on the potentially pathogenic mutations detected in 15 GB-NEC samples.

**Supplementary Table S16** Detailed information on the potentially pathogenic mutations detected in 22 GBC samples.

**Supplementary Table S17** Detailed information on mutations in genes with a potential drug response in GB-NECs.

**Supplementary Table S18** Detailed information on mutations in genes with a potential drug response in GBCs.

Supplementary Table S19 Detailed information on potential somatic SNVs.



Figure. S1.

The sequencing depth of GB-NECs and GBCs.



#### Figure. S2.

Characteristics of mutations and frequently mutated genes detected in 15 GB-NEC samples. (a) Genome-wide SNVs and INDELs discovered. From the outer circle to the inner circle: panel I: chromosome number and location; panel II: sequencing depth of the mutations; panel III: alternative allele frequency of the mutations. (b) Histograms of the number of SNVs and INDELs. (c) Histograms of the number of detailed mutation classifications. (d, e) Boxplot of the fraction of the types of SNVs, including 6 types of SNVs and transitions vs transversions. (f) Top 50 most frequently mutated genes.

а

### SNX27

	107		57		For a second sec
Human hg19	ant 🗿 accompanyamenta 🖉 🔸 🗠 🛣 🖉 a mananana 😭 👘 🖬	Ruman by00	and B overstanding strange of B + + + D I X (= 1	+ Haman hg22	🚦 eri 🚦 erislæde-islæde i slæde i sl
	* D* 10* 10* 10* 10* 10* 0* 10* 0* 10* 10*		toy ho, no no no de no to he no he fai na de la na de la		
				-	
	where where where where where where where		TARE DATE TARE TARE TARE DATE TARE TARE TARE	1	COMPLETE COM
Webl, Carrinange		MARKS, 2 Test County		BRECOMPONENT	
	and a second second second		PV13346401 Teldenes III		A
			8		a dission
	120000.00 art 1		T 1000004351		( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
undC, Law		00%EL33#80	A CALL AND A	DBMC, Joan	
			and the second		
	34		**************************************	Income	
Reflact General	INST INST	Artist Later	8931	Notice Server	6651
	anna an I	and the second second	at traven		terman line in the second s
- FRANK CARRY					
	Q/	•••	107	•••	97
e e e	ा अर्थ के क्रि. का कि क	e e e #untan bgzte	80 001 8 ootmiaacaa-miaacaa oo 2	Bunas byći	B and B and Strategies Strategies (a) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c
0 0 0 Human hgt 5		#uman bg29		Ruman byćit	
e e Ruman kgi 5		wuntan hgoth		Buman by CB	
e e e		Runan bgob	ana andre i nedere	Buman by CB	energia de la calacita de la calaci
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Ruman bgoth		e e e e e e e e e e e e e e e e e e e	
0000EL43am Envirope		Runan bgoth		Context in the second s	
Human hgi 5		eren harr		Remark hyd.8	
DBUILS of the second se		e e e e e e e e e e e e e e e e e e e		C Remarking (P	
DBBC_stam		e e e e restan togot spece, tipat trenge		anter for the form	
CONST, 4 June		e e e e restan togot septe, ti set trenge Délik, ti set		CONTENT OF CONTENT.	
000E.class.Derrige		Contrast by Contra		COURT To See The Second	
000E.clan.Drings		Definition of the second secon		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Difference of the second secon		Berger, M. Jan Franke Der K. M. Jan Franke Der K. M. Jan Franke Der K. M. Jan		Control 1 (Control 1 (Contro) (Control 1 (Control 1 (Control 1 (Control 1 (Control 1 (Control	
Delle Line Design Delle Line Design Des		eneral high			
Contracting Contra		and a hora		Berger Aller Service	
Const. Jan.		Partials high		Weight State     Weight State	

# SRPK1

b

•••			av.		•••	<i>a</i> ,
Human bijdb	B 04 6	ew6/35/858/223-35/858/285	or ∰ ◀ ⊨ @ 🖪 X 💬 I	E	Hanar Ng13	
	101 103 103 103	MO NO NO 40	en en en an an an an	and and an an an an a		
			Si be			
	0.01.010	1.00 M T	and a second second			RANGE RANGE RANGE RANGE RANGE RANGE
	1000					
OBNOC, 1.3em Enwroge	THE REAL PROPERTY AND ADDRESS OF		_		GBNDC/Glass-Grange	
			CARGE AND			That event 107
			NUCCENT: 41			6 (5 (98.4), 6 ()
			C 14(796,12+,17-)			213
			11			
						*
08N0C,1344					DBMDC_VDam	
			*			
		===				
layona 😽			****************		Departor 🚥	- ACAACCATTICICIATIES CATCATTACCOTCIENALISCONACTICIACTOCACTAC
Reflex Deve	9 4 6 4		X 6 1 8 X 3		N/Sec Berne	8891
			9440			
					100	
					Tion celo I III	Evitador Barrosa
•••					the second ball of	
The set of the	2 V#V					
			a contractor	E	reariyo	
	201 201 201 201				Human Ayur	
	201 251 201 201	. a, a, a		2011 201 201 201 201 201 201 201 201 201	Terrar igen	
	104 104 104 104				- North Hyper	
	1011 p211 p211 p201	55 CA ES 105	an en en en en en en Ha-	unine notice		tere i serene i sentre i serene i ser
	101 001 001 001	200 200 200 200 200 200 200	на <mark>на ока ока ока ока ока</mark> на <b>на ока ока ока ока</b> на ма на закона за			
GBBDC, States George	201 124 125 1201	ан <u>ан а</u> л	ал анд 400 - 400 - 400 - 400 нич — — — — — — — — — — — — — — — — — — —		MMO, NOAN Stange	
GBMIC, Vision George	201 201 201 201	ан ал ал ал	HI OLI DEI DEI DEI DEI DEI DEI DEI DEI DEI DE	5007 500 500 500 500 50 50 50 50	MMM, Marchange	
GBNDC, Water-Grange	201 p31 p31 p31 001		All and and and and an all all all all all all all all all	оприте наприте Али 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - 200 - А	MMMI, Scherchunge	
diffic, dawdawge	1011 1011 1011 1011 1011	жерни – кол	AT COL AND	an an an an an ar	MMRIL TO ANT TO AND	
08400, Water Groups	201 201 201 201 201	же <u>н</u> ев.		ала <u>от от от от от</u> мили <u>кори</u> <u>и</u>	and it, to see to ange	
0890, therefore a pr	1 101 101 101 100 100	AND		2007 200 201 200 200 200 200 200 200 200 200	MMO, where the app	
GRAD, shareforenge	- 100 - 100 - 200	200 100 100 40 200 100 100			and, starting	
GRAD, shan Grange GRAD, shan Grange		nere ner			ange, wantinange	
GRID, share Groups					With States	
GROU, shareforenge GROU, share					Minter Ny La	
GMR, sharedwarp GMR, share	1 101 101 101 101 101 101 101 101 101 1	and the second s			ARADI, Water Stronge	
GMC, shareGroup GMC, share					With the second	
GRUC, chan Grange GRUC, chan GRUC, chan					Annon 4	
GRAD, diserdences ORIQUITORIA ORIQUITORIA Malay kine	1				andi, stan tongo Shife, stan	
GRAD, Standaroup GRAD, Stan GRAD, Stan					And the second s	
GRAD, Standaroup GRAD, Stan	- 1997 -				and the second s	
GBIC, Standaroup GBIC, Standaroup Stratoly Managenesi					And the second s	
0000_silansianayy 9000_silansi Negata					And the second s	
0005, therefore any 0005, there between the second se					In the second se	

# С

# COQ6

		£4		• • •			10V		1		KA'	
Famar hg18	B 04/14 B 04/14/74,422,184-74,422,223	0 🖆 • F 🕸 🖬 X 💬 I		Harrian hgt.9	dhr14	aviences, solar N. 403, FG	∞ # + + Φ E x 🖂 I		Harnar bg09	ewid B 08/34/74/427.863-79.427.883	o ∰ • • ⊕ Ē x 💬 l	E
		en en en en en en	en en ant en als		pol para		an an an an	en en en en en en		an an an an an an	का का का का का का का	
		410	NUM		•					National Notice Notice Notice	NUT NOT NOT NOT	NATION IN NATIONAL
GMECT are lowered	**	T da da V(21336 Totaloan Em C da da V(2136 C da da V(2136) V 131008, 2014, 2014 N d	ti i i i i i i i i i i i i i i i i i i	MEC, Line Derroge	**		Matter Coll 231       Tara control 19       C 400 (NK) (Mr.) (Mr.)       C 100 (NK) (Mr.) (Mr.)       C 100 (NK) (Mr.) (Mr.)       N 200 (Nr.) (Mr.)       N 200 (Nr.) (Mr.)		COMPLEX Son Townspe		014.14.22.27 Tel case 314 4.1 5.10(104.14-2) 5.10(104.14-2	
ONE, then				NC,104			:		0900,3344		i r r	
Segundo 🕶			• • • • • • • • • • • • • • •	nganga 📫					Pepano · · · ·			A 9 7 6 A
Those Rates	10000234		NOT A LATER OF	Non Kathol Million	N/N/N/202	· · · · · · · · · · · · · · · · · · ·		[row or car	- valo kaled	evit-Natura		TOR & LATER

# d

## EIF5AL1

•••	67	•••	104	•••	10v
Human bg29	• • • • • • • • • • • • • • • • • • •	Former hg15	B 0+19 B 0+225,222,445-11,222,445 G 🔮 + > ⊕ 🗖 X 🗁 I	Human hg29	2 (w10) ☐ (w1001,222,400-01,222,456 Ge 昔 + > (0) ☐ × [D] 1
					the first the trie trie trie trie too too the trie trie trie trie trie trie the
	- Ho				Пар начине начине начине
allelit, i san Gowage		DENEC, Case Dramage			
9890(1.13an		indi, i san		10001_11.0a	
			· · ·		
native ( denor	6 6 6 A A 6 A 1 6 A A A 6 6 A A 1 6 A 6	lagana 🔺 Wilay Jana	сссь х с х т с к х х а а к х т а х с 	Ballag Carrel	CATCATCATCATCATCATCATCATCATCATCATCATCATC
tests haded 1885	oruna fator cra	THOM BADO HER	ignorous I	i banda hanimi	1410F12E308

# Figure. S3.

Detailed mutation information of several SMGs by IGV.







## Figure. S5.

Detailed information on the mutations in the top 50 most frequently mutated genes in 22 GBC samples.



#### Figure. S6.

(a) Venn diagram of mutations detected in GB-NECs and GBCs. (b) Pathway enrichment analysis of genes mutated specifically in GB-NECs. The length of the column represents the -log10(p-value) of the enriched pathways. The number on the right side of the column represents the number of mutated genes detected in the pathway. (c) Pathway enrichment analysis of genes mutated in both GB-NECs and GBCs.



# Figure. S7.

The mutation information of the top 50 cancer-related genes by mutation frequency in GBCs.



## Figure. S8.

IHC results (magnification 200×) of RB1 in *RB1* wild-type/mutant GB-NEC samples. Scale bars in the figures indicate 100  $\mu$ m.



# Figure. S9.

IHC results (magnification 200×) of NAB2 in *NAB2* wild-type/mutant GB-NEC samples. Scale bars in the figures indicate 100  $\mu$ m.



## Figure. S10.

The mutation information of the *ERBB* family in GB-NECs and GBCs.







#### Figure. S11.

3

9

Combined enrichment analysis of genes with copy number gain and loss in GB-NECs and GBCs.





## Figure. S13.

Detailed mutation information of genes mutated in the 22 GBC samples and with potential clinically actionable mutations recorded in the OncoKB database.



# Figure. S14.

Mutations of N-stage related genes in GB-NECs of T1/T2 and T3/T4 stages.



## Figure. S15.

Genes specifically mutated in GBCs with the N0 and N1/N2 stages. Genes with mutation frequency > 30% in each group are shown.



## Figure. S16.

Survival analysis of patients with *MYH11/KDM6A/XPC* mutations respectively compared with those without mutations of these genes.



Figure. S17.

Survival analysis of GB-NEC patients with CNVs of AAMDC compared with those with wild type AAMDC.



#### Figure. S18.

Mutation frequency and survival analysis of enriched signaling pathways of genes specifically mutated in GB-NECs.



# Figure. S19.

The mutation signatures discovered in each GB-NEC sample.



#### Figure. S20.

Enrichment analysis of known oncogenic signaling pathways in TCGA cohorts. The horizontal axis represents the total number of genes in the pathway and the vertical axis represents the number of genes mutated in the corresponding pathway. The size of the circle represents the percentage of mutated genes in all genes of the pathway, the detailed number of which is also labeled after the pathway name.